FDA inspection
Allergan Sales, LLC: FDA inspection ending Nov 15, 2002
FDA inspection 246489 · No Action Indicated (NAI) · Irvine, CA
Key facts
| Inspection ID | 246489 |
|---|---|
| Firm | Allergan Sales, LLC |
| FEI number | 2011068 |
| Address | 2525 Dupont Dr |
| City | Irvine |
| State | CA |
| ZIP | 92612-1531 |
| Fiscal year | 2003 |
| Inspection end date | Nov 15, 2002 |
| Classification | No Action Indicated (NAI) |
| Project area | Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs |
| Product type | Drugs |
At a glance
- None Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 10–99 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data